Schroder Investment Management Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-303,534
Closed -$783K – 1423
2017
Q2
$783K Sell
303,534
-107,762
-26% -$248K ﹤0.01% 1010
2017
Q1
$888K Buy
411,296
+279,863
+213% +$619K ﹤0.01% 969
2016
Q4
$279K Sell
131,433
-15,848
-11% -$44.2K ﹤0.01% 1012
2016
Q3
$493K Sell
147,281
-67,598
-31% -$215K ﹤0.01% 974
2016
Q2
$675K Sell
214,879
-52,056
-20% -$174K ﹤0.01% 947
2016
Q1
$846K Buy
+266,935
New +$832K ﹤0.01% 933
2015
Q1
– Sell
-8,684,695
Closed -$67M – 1416
2014
Q4
$67M Sell
8,684,695
-37,500
-0.4% -$297K 0.13% 196
2014
Q3
$65.2M Sell
8,722,195
-6,945
-0.1% -$64.5K 0.09% 215
2014
Q2
$84.5M Sell
8,729,140
-67,900
-0.8% -$605K 0.11% 177
2014
Q1
$73.1M Buy
8,797,040
+3,675,872
+72% +$31.5M 0.08% 199
2013
Q4
$43.2M Buy
5,121,168
+852,600
+20% +$7.19M 0.05% 286
2013
Q3
$34M Buy
4,268,568
+805,200
+23% +$6.47M 0.08% 297
2013
Q2
$26.7M Buy
+3,463,368
New +$27M 0.07% 330

Other funds holding PDLI

Schroder Investment Management Group's PDLI Position: Q3 2017 in Review

Schroder Investment Management Group sold out of PDL BioPharma, Inc. (PDLI) in Q3 2017, closing a stake of 303,534 shares — an estimated $783K sold.

Schroder Investment Management Group first reported a position in PDLI in Q2 2013 and held it in 13 quarters. The position peaked at $84.5M in Q2 2014. 186 funds tracked by Wall St. Rank hold PDLI as of Q3 2017.

  • Schroder Investment Management Group reported no remaining PDL BioPharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Schroder Investment Management Group sold 303,534 PDL BioPharma, Inc. shares in Q3 2017, an estimated $783K.
  • Schroder Investment Management Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 13 quarters.
  • Schroder Investment Management Group's PDL BioPharma, Inc. position peaked at $84.5M in Q2 2014.
  • 186 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2017.

Based on Schroder Investment Management Group's 13F filing for Q3 2017, filed 9 Nov 2017.